Safe Prescribing — MCQs
On this page
A 68-year-old man with atrial fibrillation is on dabigatran 150mg twice daily. He is admitted with a large intracranial haemorrhage with midline shift on CT scan. He is deteriorating neurologically and neurosurgery is considering emergency evacuation. His last dose of dabigatran was 4 hours ago. His eGFR is 58 ml/min/1.73m². Which is the most appropriate immediate management?
A 45-year-old man with newly diagnosed type 1 diabetes is being initiated on basal-bolus insulin. His HbA1c is 98 mmol/mol (11.2%). He weighs 76kg. He is nervous about starting insulin and asks for the lowest possible starting doses. What total daily insulin dose would you recommend initially?
A 59-year-old woman with mechanical mitral valve replacement is on warfarin with target INR 3.0-4.0. She presents to the emergency department with epistaxis for 3 hours that has not stopped with local measures. Her INR is 7.2. Her haemoglobin is 118 g/L (baseline 135 g/L). She is haemodynamically stable. What is the most appropriate immediate management of her elevated INR?
A 56-year-old woman with type 2 diabetes is on insulin glargine 34 units at bedtime and metformin 1g twice daily. She is scheduled for colonoscopy with sedation at 2pm. She has been nil by mouth since midnight. What is the most appropriate insulin management on the day of the procedure?
A 74-year-old man with atrial fibrillation on apixaban 5mg twice daily is admitted with acute cholecystitis requiring emergency cholecystectomy. His last dose of apixaban was 14 hours ago. His renal function is normal (eGFR 68 ml/min/1.73m²). When is it safe to proceed with surgery?
A 67-year-old man with deep vein thrombosis is established on rivaroxaban 15mg twice daily (day 18 of treatment). He has normal renal function. What is the most appropriate next step in his anticoagulation management?
A 53-year-old woman with newly diagnosed type 1 diabetes is being discharged on basal-bolus insulin therapy. She will be taking insulin glargine 22 units at bedtime and insulin aspart before meals. When should she administer the insulin aspart in relation to eating?
A 62-year-old man on warfarin for atrial fibrillation attends for INR check. His INR is 1.8 (target 2-3). He reports he has been taking co-trimoxazole for a urinary tract infection prescribed by his GP 5 days ago. What is the most likely explanation for his subtherapeutic INR despite the drug interaction?
A 70-year-old man with type 2 diabetes on basal-bolus insulin therapy is admitted with community-acquired pneumonia. His inflammatory markers are significantly elevated. He is alert and eating normally. Which aspect of his insulin management requires particular attention during acute illness?
A 65-year-old woman with atrial fibrillation is commenced on edoxaban 60mg once daily. She weighs 58kg and has normal renal function. After 3 months, her weight has decreased to 55kg. What is the most appropriate action regarding her anticoagulation?
Safe Prescribing UK Medical PG Practice Questions and MCQs
Question 111: A 68-year-old man with atrial fibrillation is on dabigatran 150mg twice daily. He is admitted with a large intracranial haemorrhage with midline shift on CT scan. He is deteriorating neurologically and neurosurgery is considering emergency evacuation. His last dose of dabigatran was 4 hours ago. His eGFR is 58 ml/min/1.73m². Which is the most appropriate immediate management?
- A. Administer idarucizumab 5g intravenously and proceed to emergency surgery (Correct Answer)
- B. Administer andexanet alfa and proceed to emergency surgery
- C. Administer prothrombin complex concentrate 50 units/kg and proceed to surgery
- D. Wait 12 hours since last dabigatran dose before considering surgery
- E. Administer tranexamic acid 1g intravenously and proceed to emergency surgery
Explanation: ***Administer idarucizumab 5g intravenously and proceed to emergency surgery***- **Idarucizumab** is a specific and immediate reversal agent for **dabigatran**, directly neutralizing its anticoagulant effect.- This immediate administration is crucial for **life-threatening bleeding**, such as an intracranial haemorrhage with midline shift, requiring urgent surgical intervention.*Administer andexanet alfa and proceed to emergency surgery*- **Andexanet alfa** is specifically indicated for the reversal of **Factor Xa inhibitors** (e.g., rivaroxaban, apixaban), not for dabigatran.- Administering this agent for dabigatran-induced bleeding would be ineffective and inappropriate, delaying the correct treatment.*Administer prothrombin complex concentrate 50 units/kg and proceed to surgery*- **Prothrombin complex concentrate (PCC)** is primarily used for **warfarin reversal** or in cases of Factor Xa inhibitor overdose when specific agents are unavailable.- PCC has **limited or unproven efficacy** in reversing dabigatran and is not recommended when a specific reversal agent like idarucizumab is accessible.*Wait 12 hours since last dabigatran dose before considering surgery*- Delaying emergency surgery in a patient with **neurological deterioration** and **midline shift** would significantly increase the risk of irreversible brain damage and mortality.- Although dabigatran has a half-life of 12-17 hours (potentially longer with mild renal impairment), active reversal is mandatory for **emergent procedures**.*Administer tranexamic acid 1g intravenously and proceed to emergency surgery*- **Tranexamic acid** is an antifibrinolytic agent that helps stabilize clots by inhibiting fibrinolysis but does not reverse the **anticoagulant effect** of dabigatran.- It is insufficient as a standalone therapy for significant bleeding caused by a direct thrombin inhibitor and would not be the primary immediate management.
Question 112: A 45-year-old man with newly diagnosed type 1 diabetes is being initiated on basal-bolus insulin. His HbA1c is 98 mmol/mol (11.2%). He weighs 76kg. He is nervous about starting insulin and asks for the lowest possible starting doses. What total daily insulin dose would you recommend initially?
- A. 0.2-0.3 units/kg/day (15-23 units total daily dose)
- B. 0.4-0.6 units/kg/day (30-46 units total daily dose) (Correct Answer)
- C. 0.8-1.0 units/kg/day (61-76 units total daily dose)
- D. 1.2-1.5 units/kg/day (91-114 units total daily dose)
- E. The starting dose should be determined by the fasting glucose level only
Explanation: ***0.4-0.6 units/kg/day (30-46 units total daily dose)***- For a newly diagnosed patient with **Type 1 Diabetes**, the standard recommended starting **Total Daily Dose (TDD)** is **0.4 to 0.6 units/kg/day**.- This dose provides a safe balance between achieving glycemic control (given his high **HbA1c of 11.2%**) and minimizing the risk of severe **hypoglycemia** during the initiation phase.*0.2-0.3 units/kg/day (15-23 units total daily dose)*- This lower range is usually reserved for the "**honeymoon period**" where there is significant residual beta-cell function, which is less likely given the patient's high presentation HbA1c.- Starting at this dose would likely lead to persistent **hyperglycemia** and fail to meet the metabolic demands of a 76kg adult.*0.8-1.0 units/kg/day (61-76 units total daily dose)*- Such high doses are typically required only in cases of significant **insulin resistance**, severe **obesity**, or during acute **intercurrent illness** (e.g., sepsis).- Using this as a starting dose for a newly diagnosed patient would carry a very high risk of **treatment-induced hypoglycemia**.*1.2-1.5 units/kg/day (91-114 units total daily dose)*- This range is far beyond typical initiation protocols and is generally only seen in **adolescents during growth spurts** or patients with extreme insulin resistance.- Initiating at this level in a nervous patient would be unsafe and could lead to life-threatening **hypoglycemic episodes**.*The starting dose should be determined by the fasting glucose level only*- Relying solely on **fasting glucose** ignores the insulin requirements for meals and the overall metabolic state reflected by the weight and **HbA1c**.- A **weight-based calculation** (basal-bolus split) is the established standard for safely initiating therapy in Type 1 Diabetes to cover both **basal** and **prandial** needs.
Question 113: A 59-year-old woman with mechanical mitral valve replacement is on warfarin with target INR 3.0-4.0. She presents to the emergency department with epistaxis for 3 hours that has not stopped with local measures. Her INR is 7.2. Her haemoglobin is 118 g/L (baseline 135 g/L). She is haemodynamically stable. What is the most appropriate immediate management of her elevated INR?
- A. Withhold warfarin and administer oral vitamin K 1-3mg
- B. Withhold warfarin and administer intravenous vitamin K 5mg (Correct Answer)
- C. Withhold warfarin, administer intravenous vitamin K 5mg, and give prothrombin complex concentrate
- D. Withhold warfarin only and recheck INR in 24 hours
- E. Continue warfarin at reduced dose and give fresh frozen plasma
Explanation: ***Withhold warfarin and administer intravenous vitamin K 5mg***- In patients with **major bleeding** (such as persistent epistaxis causing a drop in haemoglobin) and a significantly elevated **INR**, the immediate goal is rapid reversal of anticoagulation.- **Intravenous vitamin K** acts faster than oral vitamin K, typically beginning to reduce the INR within 6-8 hours by promoting the synthesis of **vitamin K-dependent clotting factors**.*Withhold warfarin and administer oral vitamin K 1-3mg*- **Oral vitamin K** is generally reserved for patients with an INR > 8.0 who have **no bleeding** or only minor bleeding.- In the presence of **active major bleeding**, pharmacological reversal must be more rapid, making the oral route insufficient compared to the **intravenous route**.*Withhold warfarin, administer intravenous vitamin K 5mg, and give prothrombin complex concentrate*- While **Prothrombin Complex Concentrate (PCC)** is the gold standard for **life-threatening bleeding** or intracranial hemorrhage, it is often reserved for patients who are **haemodynamically unstable**.- Since this patient is **haemodynamically stable**, intravenous vitamin K is the most appropriate first-line active intervention to manage the risk while monitoring for clinical deterioration.*Withhold warfarin only and recheck INR in 24 hours*- Simply **withholding warfarin** is only appropriate for patients with a mildly elevated INR (usually < 5.0) and **no bleeding**.- Because the INR is 7.2 and there is **clinically significant bleeding**, passive monitoring alone puts the patient at high risk for further blood loss or complications.*Continue warfarin at reduced dose and give fresh frozen plasma*- **Fresh frozen plasma (FFP)** is no longer the preferred agent for warfarin reversal as it is less effective than PCC and carries risks of **volume overload** and transfusion-related lung injury.- **Continuing warfarin** at any dose is contraindicated when a patient presents with an **supratherapeutic INR** and active bleeding.
Question 114: A 56-year-old woman with type 2 diabetes is on insulin glargine 34 units at bedtime and metformin 1g twice daily. She is scheduled for colonoscopy with sedation at 2pm. She has been nil by mouth since midnight. What is the most appropriate insulin management on the day of the procedure?
- A. Omit morning metformin and reduce insulin glargine to 50% of usual dose given at usual time (Correct Answer)
- B. Omit metformin and give insulin glargine at usual dose at usual time
- C. Omit all diabetes medications until after the procedure
- D. Give insulin glargine at 50% dose in the morning rather than at usual bedtime
- E. Switch to variable rate intravenous insulin infusion from midnight
Explanation: ***Omit morning metformin and reduce insulin glargine to 50% of usual dose given at usual time*** - For patients undergoing procedures requiring fasting, **basal insulin** (glargine) should be reduced (typically by 20-50%) to account for reduced caloric intake while preventing **hyperglycemia** and ketosis. - **Metformin** is generally omitted on the day of the procedure to minimize the risk of **lactic acidosis** and gastrointestinal side effects during fasting and sedation. *Omit metformin and give insulin glargine at usual dose at usual time* - Maintaining the full dose of **insulin glargine** during a prolonged fast significantly increases the risk of **hypoglycemia** during the procedure. - While metformin should be omitted, the basal insulin dose must be adjusted downwards to maintain safety while **Nil by Mouth (NBM)**. *Omit all diabetes medications until after the procedure* - Omitting all insulin in a patient with Type 2 Diabetes on a significant insulin dose can lead to severe **uncontrolled hyperglycemia** or potential **ketosis**. - Basal insulin provides the necessary **background insulin** required for metabolic processes unrelated to meals. *Give insulin glargine at 50% dose in the morning rather than at usual bedtime* - Changing the **timing of administration** for a long-acting analogue like glargine is unnecessary and can complicate the insulin profile for the following 24 hours. - The dose reduction should ideally occur at the **usual administration time** to maintain a steady state of insulin delivery. *Switch to variable rate intravenous insulin infusion from midnight* - A **Variable Rate Intravenous Insulin Infusion (VRIII)** is usually reserved for prolonged fasting (missing more than one meal) or for patients with **Type 1 Diabetes** undergoing major surgery. - For a routine day-case procedure like a colonoscopy in a **Type 2 diabetic**, VRIII is overly invasive and carries its own risks like fluid overload or electrolyte disturbances.
Question 115: A 74-year-old man with atrial fibrillation on apixaban 5mg twice daily is admitted with acute cholecystitis requiring emergency cholecystectomy. His last dose of apixaban was 14 hours ago. His renal function is normal (eGFR 68 ml/min/1.73m²). When is it safe to proceed with surgery?
- A. Surgery can proceed immediately as 14 hours is sufficient (Correct Answer)
- B. Wait until 24 hours after the last dose before proceeding
- C. Wait until 48 hours after the last dose before proceeding
- D. Wait until 72 hours after the last dose before proceeding
- E. Administer idarucizumab to reverse the anticoagulation before emergency surgery
Explanation: ***Surgery can proceed immediately as 14 hours is sufficient*** - In an **emergency surgical** context, a time interval of >12 hours since the last dose of **apixaban** is generally considered acceptable for proceeding, as the peak effect occurs at 3-4 hours and levels have significantly declined. - With a **half-life** of approximately 12 hours and preserved **renal function** (eGFR >60), the anticoagulant effect at 14 hours is reduced enough to balance the risks of surgical bleeding against the risks of delaying emergency treatment for cholecystitis. *Wait until 24 hours after the last dose before proceeding* - While 24 hours provides a larger safety margin, it is not strictly required for an **emergency procedure** when more than 12 hours have already elapsed. - Delaying emergency surgery for an extra 10 hours may increase the risk of **gallbladder perforation** or sepsis in the setting of acute cholecystitis. *Wait until 48 hours after the last dose before proceeding* - This protocol is typically reserved for **elective surgeries** with a **high bleeding risk** where complete clearance of the drug (approximately 4-5 half-lives) is desired. - Following this timeline in an **emergency setting** would represent an unnecessary and potentially dangerous delay in surgical intervention. *Wait until 72 hours after the last dose before proceeding* - A 72-hour delay is generally only considered for patients with **severe renal impairment** (CrCl <30 mL/min) undergoing very high-risk procedures. - The patient's **eGFR of 68 ml/min** indicates sufficient renal clearance, making such a long wait clinically inappropriate. *Administer idarucizumab to reverse the anticoagulation before emergency surgery* - **Idarucizumab** is a specific reversal agent for **dabigatran** (a direct thrombin inhibitor) and has no efficacy against **apixaban**, which is a **Factor Xa inhibitor**. - The specific reversal agent for apixaban is **andexanet alfa**, but it is generally reserved for life-threatening or uncontrolled bleeding rather than preparing for surgery at 14 hours post-dose.
Question 116: A 67-year-old man with deep vein thrombosis is established on rivaroxaban 15mg twice daily (day 18 of treatment). He has normal renal function. What is the most appropriate next step in his anticoagulation management?
- A. Continue rivaroxaban 15mg twice daily for a total of 3 weeks, then switch to 20mg once daily (Correct Answer)
- B. Continue rivaroxaban 15mg twice daily for a total of 6 weeks, then switch to 20mg once daily
- C. Switch immediately to rivaroxaban 20mg once daily as he is beyond the initial treatment phase
- D. Continue rivaroxaban 15mg twice daily for the entire treatment duration
- E. Switch to warfarin with target INR 2-3 after completing 3 weeks of rivaroxaban
Explanation: ***Continue rivaroxaban 15mg twice daily for a total of 3 weeks, then switch to 20mg once daily***- For acute **deep vein thrombosis (DVT)**, the standard initiation dose of **rivaroxaban** is **15mg twice daily** for the first **21 days (3 weeks)**.- This initial aggressive dosing ensures effective anticoagulation during the period of highest risk for clot propagation and is followed by a **maintenance dose of 20mg once daily**.*Continue rivaroxaban 15mg twice daily for a total of 6 weeks, then switch to 20mg once daily*- Extending the **15mg twice-daily** dosing to 6 weeks is not aligned with established guidelines for **rivaroxaban** in **DVT** treatment.- This prolonged higher dose increases the **risk of bleeding** without offering additional benefit over the standard 3-week initial phase.*Switch immediately to rivaroxaban 20mg once daily as he is beyond the initial treatment phase*- The patient is on **day 18** of treatment; the initial intense phase of **rivaroxaban 15mg twice daily** is for **21 days**.- Switching prematurely would mean the patient receives a sub-therapeutic dose during the critical final days of the **acute treatment phase**, increasing the risk of recurrent thrombosis.*Continue rivaroxaban 15mg twice daily for the entire treatment duration*- Maintaining the **15mg twice-daily** dose for the entire treatment duration (typically 3-6 months or longer) is an incorrect and excessive regimen.- Long-term use of this higher dose substantially increases the cumulative **risk of major bleeding** and is not standard practice.*Switch to warfarin with target INR 2-3 after completing 3 weeks of rivaroxaban*- **Rivaroxaban** is a **direct oral anticoagulant (DOAC)**, often preferred for DVT due to its predictable pharmacokinetics and no need for routine **INR monitoring**.- There is no indication to switch to **warfarin** in a patient tolerating rivaroxaban with normal renal function, as DOACs are equally or more effective and often safer.
Question 117: A 53-year-old woman with newly diagnosed type 1 diabetes is being discharged on basal-bolus insulin therapy. She will be taking insulin glargine 22 units at bedtime and insulin aspart before meals. When should she administer the insulin aspart in relation to eating?
- A. 30-45 minutes before meals
- B. Immediately before or with the first mouthful of food (Correct Answer)
- C. Midway through the meal
- D. Immediately after finishing the meal
- E. 30 minutes after completing the meal
Explanation: ***Immediately before or with the first mouthful of food*** - **Insulin aspart** is a **rapid-acting insulin analogue** with a very quick onset of action (10–20 minutes), designed to cover the rapid postprandial glucose surge. - Administering it right as the meal begins ensures its peak action coincides with the digestion and absorption of carbohydrates, optimizing **postprandial glucose control** and preventing early **hyperglycemia**. *30-45 minutes before meals* - This timing is typically appropriate for **soluble (regular) insulin**, which has a slower onset of action (30-60 minutes) and requires a longer lead time before food. - Giving **rapid-acting insulin aspart** this early would significantly increase the risk of **pre-meal hypoglycemia** before the consumed carbohydrates can raise blood glucose levels. *Midway through the meal* - Administering insulin aspart midway through the meal would delay its action relative to the initial carbohydrate absorption, potentially leading to **early postprandial hyperglycemia**. - While occasionally considered in specific clinical scenarios (e.g., severe gastroparesis), it is not the standard or optimal recommendation for general postprandial glucose management. *Immediately after finishing the meal* - Taking **insulin aspart** after completing the meal means its peak action will occur too late to effectively cover the initial and rapid **postprandial glucose rise**, resulting in undesirable hyperglycemia. - This delayed timing can lead to a mismatch between insulin action and carbohydrate absorption, making it harder to achieve stable glucose control. *30 minutes after completing the meal* - This significantly delayed administration would result in a prolonged period of **hyperglycemia** following the meal, as the insulin's peak effect would be far behind the carbohydrate absorption. - Such a substantial delay leads to poor glucose management, with potential for high blood glucose levels post-meal and an increased risk of **delayed hypoglycemia** hours later.
Question 118: A 62-year-old man on warfarin for atrial fibrillation attends for INR check. His INR is 1.8 (target 2-3). He reports he has been taking co-trimoxazole for a urinary tract infection prescribed by his GP 5 days ago. What is the most likely explanation for his subtherapeutic INR despite the drug interaction?
- A. Co-trimoxazole typically causes INR elevation; the low INR suggests non-compliance with warfarin (Correct Answer)
- B. The timing is too early; co-trimoxazole takes 7-10 days to affect INR
- C. Co-trimoxazole reduces warfarin absorption from the gastrointestinal tract
- D. The patient has likely increased his vitamin K intake during the infection
- E. Co-trimoxazole is a weak enzyme inducer causing increased warfarin metabolism
Explanation: ***Co-trimoxazole typically causes INR elevation; the low INR suggests non-compliance with warfarin*** - **Co-trimoxazole** (trimethoprim/sulfamethoxazole) is a potent **CYP2C9 inhibitor**, which significantly reduces the metabolism of **warfarin's S-isomer**, leading to a **marked increase in INR**. - Given that the expected outcome of co-trimoxazole use in a patient on warfarin is a **supratherapeutic INR**, a subtherapeutic INR of 1.8 strongly suggests **non-compliance** or omission of warfarin doses by the patient. *The timing is too early; co-trimoxazole takes 7-10 days to affect INR* - The **pharmacokinetic interaction** between co-trimoxazole and warfarin typically manifests quite rapidly, with a significant **INR elevation** often observed within **3 to 5 days** of starting co-trimoxazole. - Therefore, after 5 days, the effect should already be apparent, making the claim that it's "too early" incorrect. *Co-trimoxazole reduces warfarin absorption from the gastrointestinal tract* - There is **no clinical evidence** to support that co-trimoxazole interferes with the **gastrointestinal absorption** of warfarin. - The primary and significant interaction occurs at the **metabolic level** in the liver, not at the absorption site. *The patient has likely increased his vitamin K intake during the infection* - While an increase in **dietary vitamin K** can indeed lower INR, it is generally **unlikely** for a patient with an acute urinary tract infection to suddenly and significantly increase their vitamin K intake. - This explanation is less probable compared to the direct and potent drug-drug interaction expected or the possibility of **non-compliance**. *Co-trimoxazole is a weak enzyme inducer causing increased warfarin metabolism* - **Co-trimoxazole** is a well-known **enzyme inhibitor** (specifically of CYP2C9), not an enzyme inducer. - As an inhibitor, it would **decrease warfarin metabolism**, leading to **increased warfarin levels** and a higher INR, which is the opposite effect of enzyme induction.
Question 119: A 70-year-old man with type 2 diabetes on basal-bolus insulin therapy is admitted with community-acquired pneumonia. His inflammatory markers are significantly elevated. He is alert and eating normally. Which aspect of his insulin management requires particular attention during acute illness?
- A. Insulin should be temporarily discontinued until the acute illness resolves
- B. Only basal insulin should be continued; bolus insulin should be stopped
- C. Insulin requirements typically increase during acute illness and infection (Correct Answer)
- D. Insulin dose should be halved to prevent hypoglycaemia during reduced oral intake
- E. Insulin should be switched to twice-daily premixed insulin for simplicity
Explanation: ***Insulin requirements typically increase during acute illness and infection*** - Acute illness, particularly infection like pneumonia, activates a **stress response** leading to the release of **counter-regulatory hormones** (e.g., cortisol, glucagon). These hormones significantly increase **insulin resistance** and glucose production. - Even with normal oral intake, this heightened physiological stress means that patients with diabetes usually require **higher insulin doses** to maintain adequate glycemic control and prevent hyperglycemia. *Insulin should be temporarily discontinued until the acute illness resolves* - Discontinuing insulin therapy in a patient with type 2 diabetes on basal-bolus insulin is extremely dangerous during acute illness, potentially precipitating **diabetic ketoacidosis (DKA)** or **hyperosmolar hyperglycemic state (HHS)**. - **Basal insulin** is continuously needed to suppress hepatic glucose output and ketogenesis, regardless of whether the patient is eating. *Only basal insulin should be continued; bolus insulin should be stopped* - Since the patient is reported to be **alert and eating normally**, **bolus insulin** is crucial to cover the carbohydrate intake and manage **postprandial glucose excursions**. - Stopping bolus insulin while eating would inevitably lead to severe **postprandial hyperglycemia**, worsening overall glycemic control during the illness. *Insulin dose should be halved to prevent hypoglycaemia during reduced oral intake* - The patient is explicitly stated to be **eating normally**, contradicting the premise of reduced oral intake. Therefore, arbitrarily halving the insulin dose is inappropriate. - Given the typical **increase in insulin requirements** during acute illness, such a drastic reduction would likely result in significant **hyperglycemia** rather than preventing hypoglycemia. *Insulin should be switched to twice-daily premixed insulin for simplicity* - During an acute illness in a hospital setting, a **basal-bolus insulin regimen** offers superior flexibility, allowing for precise adjustments to both basal and bolus doses based on frequent blood glucose monitoring and varying nutritional needs. - Switching to a **premixed insulin regimen** would limit this flexibility, making it more challenging to achieve optimal glycemic control in a rapidly changing clinical situation.
Question 120: A 65-year-old woman with atrial fibrillation is commenced on edoxaban 60mg once daily. She weighs 58kg and has normal renal function. After 3 months, her weight has decreased to 55kg. What is the most appropriate action regarding her anticoagulation?
- A. Continue edoxaban 60mg once daily unchanged
- B. Reduce edoxaban dose to 30mg once daily (Correct Answer)
- C. Switch to apixaban 5mg twice daily
- D. Switch to warfarin with target INR 2-3
- E. Stop anticoagulation and prescribe aspirin 75mg daily
Explanation: ***Reduce edoxaban dose to 30mg once daily*** - **Edoxaban** requires a dose reduction to 30mg once daily if the patient's **body weight is ≤ 60kg** to minimize the risk of bleeding while maintaining efficacy. - Since the patient's weight has decreased to **55kg**, she now meets the mandatory criterion for this dose adjustment. *Continue edoxaban 60mg once daily unchanged* - Continuing the standard 60mg dose in a patient weighing **less than 60kg** significantly increases the **bleeding risk**. - Dose adjustments for **DOACs** must be reviewed when a patient's clinical parameters, such as **weight or renal function**, change. *Switch to apixaban 5mg twice daily* - Switching to another DOAC is unnecessary as **edoxaban** remains appropriate, provided the dose is adjusted for the patient's current **weight**. - While **apixaban** is also an effective anticoagulant, its dosing also depends on criteria like age, weight, and creatinine, but simple dose adjustment of the current drug is the standard first step. *Switch to warfarin with target INR 2-3* - **Warfarin** is generally less preferred than **DOACs** for non-valvular atrial fibrillation due to the need for frequent **INR monitoring** and dietary restrictions. - There is no clinical indication to switch from a DOAC to a **Vitamin K Antagonist** solely due to a weight change, especially when the DOAC can be dose-adjusted. *Stop anticoagulation and prescribe aspirin 75mg daily* - **Aspirin** is no longer recommended for stroke prevention in **atrial fibrillation** as it is significantly less effective than anticoagulants and still carries bleeding risks. - Stopping anticoagulation entirely would leave the patient at a high risk for **cardioembolic stroke** given her history of atrial fibrillation.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free